Novel treatment strategies for malignant melanoma: A new beginning?
Authors:
- Veronique D’hondtVDVeronique D’hondt
- Pierre VereeckenPVPierre Vereecken
- Ahmad AwadaAAAhmad Awada
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 62 (1) , 16-22
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal of Cancer, 2006
- Antisense Strategies for Oncogene InactivationSeminars in Oncology, 2005
- A phase II study of bortezomib in the treatment of metastatic malignant melanomaCancer, 2005
- Temozolomide plus thalidomide in patients with brain metastases from melanomaCancer, 2005
- Will the dark sky over advanced renal cell carcinoma soon become brighter?European Journal of Cancer, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- The role of B-RAF in melanomaCancer and Metastasis Reviews, 2005
- Improving Outcomes in Advanced Malignant MelanomaDrugs, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994